Attorney Docket No.: Enz-7(P)(C3)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Certificate

In re Patent of: Elazar Rabbani et al. JUL 0 7 2006

Patent No ·

of Correction

07 LUU6

Issued:

7.064.197 B1 June 20, 2006

Serial No.:

08/486,070 June 7, 1995 Group Art Unit: 1631

Filed:

Primary Exam'r: John S. Brusca

SYSTEM, ARRAY AND NON-POROUS SOLID SUPPORT COMPRISING Title: FIXED OR IMMORILIZED NUCLEIC ACIDS

Confirmation No.:

CERTIFICATE OF FACSIMILE TRANSMISSION

Attention: CERTIFICATE OF CORRECTION BRANCH

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir

I hereby certify that the attached correspondence (total of 10 pages including this sheet) comprising:

Request Under 37 C.F.R. §1.323 For Certificate Of Correction Of Patent was sent to the United States Patent and Trademark Office by telefax to (571) 273-8300.

Respectfully submitted,

Date: July 6, 2006

Ronald C. Fedus, Reg. No. 32,567 Attorney for Applicants

Enzo Life Sciences, Inc. c/o Enzo Biochem, Inc. 527 Madison Avenue, 9th Floor New York, NY 10022-4304 Telephone (212) 583-0100

Facsimile (212) 583-0150

Enz-7(P)(C3)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Patent No.:

: 7,064,197 B1

JUL 0 6 2006

Patentee

: Rabbani et al.

Issued

June 20, 2006

Title

: SYSTEM, ARRAY AND NON-POROUS SOLID SUPPORT

: SYSTEM, ARRAY AND NON-POROUS SOLID SUPPORT
COMPRISING FIXED OR IMMOBILIZED NUCLEIC ACIDS

Serial No.:

08/486,070

: June 7, 1995

TC/Art Unit

: 1631

Examiner:

: John S. Brusca

Docket No.

: Enz-7(P)(C3)

Customer No.

: 28171

ATTN: CERTIFICATE OF CORRECTION BRANCH

Commissioner for Patents

P.O. Box 1450

Alexandria, VA. 22313-1450

REQUEST UNDER 37 CFR § 1.323 FOR CERTIFICATE OF CORRECTION OF PATENT

Sir:

Patentees respectfully request a Certificate of Correction for their aboveidentified and issued patent, U.S. Patent No. 7,064,197 B1.

In the issued patent, the sentence on the front page, "This patent is subject to a terminal disclaimer," is incorrect because no terminal disclaimer was filed in this application nor in the immediate parent to this application utilizing the serial number of this application.

With regard to the change of "Triton X-100" to "TRITON X-100 (octoxynol)," entry "6601. Octoxynol" from the Merck Index, 10th Ed., page 971, is submitted herewith and shows that "TRITON X-100" is a trade name for octoxynol.

Enz-7(P)(C3)

PAGE 2/10 * RCVD AT 7/6/2006 3:59:55 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/1 * DNIS:2738300 * CSID:2125830150 * DURATION (mm-ss):03-04

Rabbani et al., U.S. Patent No. 7,064,197 B1

Issued: June 20, 2006

Page 2 [Request Under 37 C.F.R. §1.323 For Certificate of Correction Of Patent]

Furthermore, several mistakes of an obvious typographical nature are also present and are being corrected.

The corrections submitted herein do not constitute new matter or require reexamination.

Attached are two copies of a Certificate of Correction Form PTO/SB/44 that indicate the type and location of the errors. Patentees respectfully request that the Commissioner certify these forms, and return one of the forms to the undersigned attorney.

The fee for filling this Request Under 37 C.F.R. §1.323 is §100.00 as set forth in 37 C.F.R. §1.20(a). The Patent and Trademark Office is hereby authorized to charge the requisite \$100.00 fee to Deposit Account No. 05-1135. No other fee or fees are believed due in connection with the filling of this paper. In the event that any other fee(s) is/are due, however, authorization is further given to charge the amount of such other fee(s) to Deposit Account No. 05-1135, or to credit overnavment thereto.

Respectfully submitted.

Dated: TULY 6 2006

Ronald C. Fedus

Registration No. 32,567
Attorney for Patentees

Enzo Life Sciences, Inc. c/o Enzo Biochem, Inc. 527 Madison Avenue, 9th Floor New York, NY 10022-4304 Tel.: (212) 583-0100

Fax: (212) 583-0150

Enz-7(P)(C3)

THE JUL 0 8 2006 MERCK INDEX

AN ENCYCLOPEDIA OF CHEMICALS, DRUGS, AND BIOLOGICALS

TENTH EDITION

Martha Windholz, Editor Susan Budavani, Co-Editor Rosemary F. Blumetti, Associate Editor Elizabeth S. Otterbein, Assistant Editor

Published by
MERCK & CO., INC.
RAHWAY, N.J., U.S.A.

1983

PAGE 4/10 * RCVD AT 7/6/2006 3:59:55 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-5/1 * DNIS:2738300 * CSID:2125830150 * DURATION (mm-ss):03-04

Copyright @ 1983 by Merck & Co., Inc. Previous Editions Copyright © 1940, 1952, 1960, 1968, 1976 by Marak & Co., Inc. All rights reserved. Copyright under the Universal Copyright Convention and the International Copyright Convention. Copyright centred under the Pan-American Copyright Copyright (centred Copyright) Merck & Co., Inc. Rahway, New Jersey, U.S.A. менск знаяр & DOHME West Point, Pa. MERCK SHARP & DOHME INTERNATIONAL Rahway, N. J. MERCK SHARP & DOMME RESEARCH LABORATORIES MSD AGVET DIVISION Rabway, N. J. HUBBARD FARMS, INC. Watcole, N. H. MERCK CHEMICAL MANUFACTURING DIVISION Retreay, N. J. MERCK CHEMICAL DIVISION Rehway, N. J. KELCO/AIL INTERNATIONAL LIMITED Longon, England BALTIMORE AIRCOIL GOMPANY, INC. Baldmore, Md. CALSON CARBON CORPORATION KELCO DIVISION gan Diego. Calit. 1st Edition -- 1889 2nd Edition - 1896 2nd Edition - 1896 3rd Edition - 1907 4th Edition - 1930 5th Edition - 1940 6th Edition - 1952 7th Edition~1960 8th Edition~1968 9th Edition - 1976 10th Edition-1983 Library of Congress Catalog Card Number 33-61075 ISBN Number 911910-27-1 Printed in the U.S.A. First Printing - October 1983 Second Princing - March 1984 - - 2006

PAGE 5/10 * RCVD AT 7/6/2006 3:59:55 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-5/1 * DNIS:2738300 * CSID:2125830150 * DURATION (mm-ss):03-04

thylbutyl)-2mine; M-inomethylbutylmet, M-(1,3-Ontisanylt 199.38. C plensation of

101". Strong np 121". 5cl

1193. Solidit; bpg 70.0°; bc. Chim [4]

и совра. То

6603

a-Octyl Bromide

Pree base. Intel in water.

Hydrochlesida, C₂H₂NO₂HCL, crystels, up 199-200.

Spatingly sol in water (1950). An solus are acid to librous.

THERAY CAT: Antisparandia.

6897. Octhilingan. 2-Ocyt-3CH)-inshimalony 2-ocyyt-4-inshimalin-3-ong RK-899; Kuthon. Cyth, NNS; mol wt 2113-4. C 61-935. H 8-978. N 6-575. C 7-507, 8 15.076. Frepn: S. N. Lewis et al., Pr. par, L-SSS-616 corcup to U.S. pat. 5,76L-88 (1995, 1973 to Rolmo & Thankcident, A Sterrocyti Chem. 3, 571 (1971).

Liquid, bp.as. 120°. uv max (methanol): 280 nm (log e 3.85).
USE Punginida Bioolet in cooling-cower water, paints, courting oils, councies and altemptos for institut process-them.

6538. Ociedriae. 6-Metryi-2-hupanamina 6-muhyi-2-bepyismine; 2-metryi-6-teninoheptane 6-amino-2-methylasiane 3-amino-6-methylasiane; 3-amino-6-methylasiane; 3-amino-6-methylasiane; 3-amino-6-methylasiane; 3-amino-7-methylasiane; 3-amino-7-methyla

di-Form, viscous Uquid, fishy edus, bp 154-156. ng
1,4200.
Nydrochloride, C₂N₂N.RCL, crystals, sol in water. LD₂,
Lo. to mice, rate, 59, 41.5 mg/kg, E. J. Fellows, loc. ok
Sullate, C₂N₂N.M.S.O₂, crystals, sol in water.
TREAT CAT: Advances (viscous strictor), local anostestic.

thetic.

6599. Octopunità. « definition this)» « hybrogrimanymarkanti « deminion this)» « hybrogrimanymarkanti « deminion this)» « hybrogrimany i etcolor) (- demarkanti » (- deminion this)» » (- deminion this)

(- deminion this » (- deminion this » (- deminion this)

(- deminion this » (- de

n(-)-Form, crystals from hot water which change at about 160° to a compel which malts at >250° facel, [cdf] --2.60° (ii). N 150°. -3.74° (iii). Profess hydrochicalds, Cdf, ClnO, Epiceros, Nordes, Mayfes, Nepptiers (ampatia). Grischia doc 170°. Printy tol in white.

This of the compelant of the

Tatalas Ort. Advancage.

600. Oddistina. 6-Lécyfishi-b-[12-[llowmipo-amaly1-5-pyric-dicty] methyllomydmia] - 1-b-bybray.

maly1-5-pyric-dicty] methyllomydmia] - 1-b-bybray.

600. The state of the stat

Ceysbar, mp 105-105°. tw max: 234, 277 am (£ 16,200. 320). Rydrochlorida, C., H., N., O.S., H.C.b. crystale from either + bi ethmol, mp 134.3-135°. uv max: 233 nm (£ 23,000). maxar Cor. Loog-acking oral chiamine.

6001. Octobrool. a [4-(1,1,3,3-14/mmthyllac)4]abasyll-a hydroxyshylcar, 1,3-cthanaisyll, octylphanaxy polyectorysthaniol polychylane (gyool p-iscorytyhany) etha. Pryst by reasing isooctylphenol with ethylan calde. Refs. nomenikatus, ny anoxyrool. Travientyla for actica of consynoli tuclude [ugui Cd, Pulylargout 6]. Prism X.

$$\operatorname{ca}^2(\operatorname{ca}^2)^2\operatorname{del}^{\operatorname{ca}^2}_{\operatorname{\underline{A}}^2} - \circ (\operatorname{ca}^2\operatorname{ca}^2\operatorname{o})^{\overline{a}}_3$$

Octonyand (N.P.), entirency in which of maps from 5 to 12, octange comp. (a = 10). Call, Co.; are, not by 467. Find octange comp. (a = 10). Call, Co.; are, not by 467. Find octange comp. (a = 10). Call, Co.; are not be a compared by the roles, part of the pa

DERAY CATT opermentation.

602. Detyl Annials. Aurio celd ar-etylkoryl ester 2civilusing lasten. C., H., O.; and w. 172.3. C. O.; 72.6. B.
171.100, O. 12.5. C. (E.C.), J., 257.C., 257.C. C. C.

171.100, O. 12.5. C. (E.C.), J., 257.C., 257.C. C.

172.100, O.; and J. C.

olis. Sovem in mirrochanica forms reima, when has olis.

6603, n-Octyl Bromido. I-Bromocciona. C.H., Be; mol will also a signification of the control of the

Consult the cross index before using this section.

Page 971

נייי חיי בטעם

CV



COPY

J.S., Patent end Trademark Reduction Aus of 1865, no persons are required to response to a collection different reference file of the Representation of the Research Construction of the Representation of the Research Construction of the Representation of the Research Construction of the Research Cons

HAUTED STATES DATEM AND TRADEMARK OFFICE

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 1 of 1

PATENT NO. : 7,064,197 B1
APPLICATION NO.: 08/486.070

ISSUE DATE : June 20, 2006

INVENTOR(S) : Eleme Bebbor

NVENTOR(S) : Elazar Rabbani, Jannis G. Stavrianopoulos, Dolle Kirtikar, Kenneth H. Johnston, Barbara E. Thalenfeld

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below.

Front Page, After and Under

"(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days."

delete the sentence "This patent is subject to a terminal disclaimer."

Col. 9, line 7, after "of any hybrid probe-analyte is" and before "detectable" insert - then - .

Col. 9, line 7, after "One" and before "detection" delete "then".

Col. 9, line 8, before "technique as described" delete " - - - " .
Col. 10, EXAMPLE 3, line 35, change "Triton X-100" to - TRITON X-100 (octoxynol) - .

Col. 11, line 2, change "avidin" to - avidin- - .

Col. 11, EXAMPLE 5, line 35, change "duodecadiamine" to - dodecadiamine - .

Col. 12, EXAMPLE 6, line 32, change "isopropylalcohol" to – isopropyl alcohol – .
Col. 13, EXAMPLE 7, line 17, change "Triton X-100" to – TRITON X-100 (octoxynol) – .

Col. 13, Example 7, line 17, change 11ton x-100 to - TRITON X-100 (octoxynot) - .

Col. 13, lines 35-36, change "Triton X-100" to -- TRITON X-100 (octoxyno) -- .

Col. 13, line 33-36, change "Triton X-100" to — TRITON X-100 (octoxynol) — .

MAILING ADDRESS OF SENDER (Please do not use customer number below):

HUNTON & WILLIAMS LLP Attorney Docket No.: 59046.000003 No. of additional copies 1

1900 K Street, NW, Suite 1200 Washington, DC 20006-1109

This collection of electromation is required by 2 cmt 3.32, 1,323, and 3.32. This internation is required to statute or statute or statute to the transport of the statute of the statute

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

THE OW LUUD



Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly pursuant to the requirements of the Act, please be advised that; (1) the general authority for the collection of this information is 36 U.S.C. (20)(2), (2) furnishing of the information sized by the distribution of the information sized by the U.S. Patient and Trademark Office is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested information, the U.S. Patient and Trademark office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandoment of the application or expiration of the patient.

The information provided by you in this form will be subject to the following routine uses:

- 1. The Information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (G U.S.C. 552) and the Privacy Act (G U.S. 652a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement regolations.
- A insord in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, by whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- A record in this system of records may be disclosed, as a rouline use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- A record related to an international Application filed under the Patent Cooperation Treaty in this system of records may be discloseed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (20 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2804 and 2905. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 120(b) or issuance of a patent pursuant to 35 U.S.C. 161. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filted in an application which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or reculation.



PTO/SB/44 (04-05)

Approved for use through 04/30/2007. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1985, no persons are required to respond to a collection of information unless it displays a valid OMB control of

UNITED STATES PATENT AND TRADEMARK	OFFIC
CERTIFICATE OF CORRECTION	

Page __1_ of __1

PATENT NO. : 7.064.197 B1

APPLICATION NO.: 08/486,070

ISSUE DATE : June 20, 2006

INVENTOR(S) : Elazar Rabbani, Jannis G. Stavrianopoulos, Dolle Kirtikar, Kenneth H. Johnston, Barbara E.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Front Page, After and Under

"(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days."

delete the sentence "This patent is subject to a terminal disclaimer."

Col. 9. line 7, after "of any hybrid probe-analyte is" and before "detectable" insert - then - .

Cot. 9, line 7, after "One" and before "detection" delete "then".

Col. 9, line 8, before "technique as described" delete " - - - " Col. 10, EXAMPLE 3, line 35, change "Triton X-100" to - TRITON X-100 (octoxynol) - .

Col. 11. line 2. change "avidin" to - avidin- - .

Col. 11, EXAMPLE 5, line 35, change "duodecadiamine" to - dodecadiamine - .

Col. 12, EXAMPLE 6, line 32, change "isopropylalcohol" to - isopropyl alcohol - .

Col. 13, EXAMPLE 7, line 17, change "Triton X-100" to - TRITON X-100 (octoxynol) - . Col. 13, lines 28-29, change "Triton X-100" to - TRITON X-100 (octoxynol) - .

Col. 13, lines 35-36, change "Triton X-100" to -- TRITON X-100 (octoxynol) -- .
Col. 13, line 43, change "Triton X-100" to -- TRITON X-100 (octoxynol) -- .

MAILING ADDRESS OF SENDER (Please do not use customer number below):

HUNTON & WILLIAMS LLP Attorney Docket No.: 59046.000003 No. of additional copies 1

1900 K Street, NW, Suite 1200

Washington, DC 20006-1109

This software of information is required by 27 CPR1 3.22, 1,322, and 1,322. The intermedien is required to death or midsh a bernful by the public which is in fair crited the 38 LETON is presenting, specified concluded the proposed by 48 LECO. 22 and 27 CPR1 4. This cultificiant is estimated to late 1.0 how to complete, including pathering, respecting, and submitting the completed application form to the LEPTO. Throw all very depending upon the individual cases. Any comments on the amount of times yet receive to complete the form another suggesteror for recluding this between, about the sent of the CREST throughout the CREST CRES VA 22313-1450

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

into an AUUb

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information studied is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark. Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandomment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (6 U.S.C. 582) and the Privacy Act (6 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom or Information Act.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request trivolving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 652a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal
 agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to
 the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 290. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (#e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 50 U.S.C. 122(b) or issuance of a patient pursuant to 85 U.S.C. 131. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became shandened or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation or law or reculation.



This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

□ BLACK BORDERS
\square image cut off at top, bottom or sides
☐ FADED TEXT OR DRAWING
\square blurred or illegible text or drawing
☐ SKEWED/SLANTED IMAGES
\square COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
\square lines or marks on original document
\square reference(s) or exhibit(s) submitted are poor quality
OTHER:

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.